Ixabepilone + Bevacizumab for Ovarian, Fallopian Tube, and Peritoneal Cancer

"This trial is currently not accepting applicants. It was posted on April 3, 2017 and last updated on the 13th of April 2022. Alternatively, there are 482 clinical trials for fallopian tubes cancer and 358 studies with Bevacizumab seeking enrolment right now."

"This trial is no longer open to new participants. It was initially announced on April 3rd 2017 and was last modified on April 13th 2022. However, there are currently 482 studies recruiting patients with fallopian tubes cancer and 358 trials seeking Bevacizumab users."

"Bevacizumab is a commonly used treatment for malignant neoplasms and can help manage recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer following initial surgical resection, as well as locally advanced nonsquamous non-small cell lung cancer."

"Taking the evidence into account, our team at Power rated Bevacizumab's safety a 2. This is due to Phase 2 trial data which suggests that it is relatively safe but there has yet to be any clinical proof of its efficacy."

"The admission requirements for this experimental trial are ages 18 and above, up to a cap of 100 years."

"Initially tested in 2004 at Memoral Sloan Kettering Basking Ridge, bevacizumab's clinical trials have since grown to 1077 completed studies. In the present day, a notable proportion of these 358 active trials are being conducted out of New Haven, Connecticut."

"Eligible participants for this study must have a diagnosis of fallopian tubes cancer, be between the ages 18 and 100 years old, with an overall recruitment goal of 78 individuals."